NCT03769155View on ClinicalTrials.gov

VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

December 15, 2023

Study Completion Date

December 15, 2032

Conditions
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Interventions
BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

BIOLOGICAL

VX15/2503

Given IV

PROCEDURE

Surgery

Undergo therapeutic conventional surgery

Trial Locations (1)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Vaccinex Inc.

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER

NCT03769155 - VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma | Biotech Hunter | Biotech Hunter